Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011-2012 Pilot European Sentinel Registry

  • Georg Nickenig
  • Rodrigo Estevez-Loureiro
  • Olaf Franzen
  • Corrado Tamburino
  • Marc Vanderheyden
  • Thomas F Lüscher
  • Neil Moat
  • Susanna Price
  • Gianni Dall'Ara
  • Reidar Winter
  • Roberto Corti
  • Carmelo Grasso
  • Thomas M Snow
  • Raban Jeger
  • Stefan Blankenberg
  • Magnus Settergren
  • Klaus Tiroch
  • Jan Balzer
  • Anna Sonia Petronio
  • Heinz-Joachim Büttner
  • Federica Ettori
  • Horst Sievert
  • Maria Giovanna Fiorino
  • Marc Claeys
  • Gian Paolo Ussia
  • Helmut Baumgartner
  • Salvatore Scandura
  • Farqad Alamgir
  • Freidoon Keshavarzi
  • Antonio Colombo
  • Francesco Maisano
  • Henning Ebelt
  • Patrizia Aruta
  • Edith Lubos
  • Björn Plicht
  • Robert Schueler
  • Michele Pighi
  • Carlo Di Mario
  • Transcatheter Valve Treatment Sentinel Registry Investigators of the EURObservational Research Programme of the European Society of Cardiology

Related Research units

Abstract

BACKGROUND: The use of transcatheter mitral valve repair (TMVR) has gained widespread acceptance in Europe, but data on immediate success, safety, and long-term echocardiographic follow-up in real-world patients are still limited.

OBJECTIVES: The aim of this multinational registry is to present a real-world overview of TMVR use in Europe.

METHODS: The Transcatheter Valve Treatment Sentinel Pilot Registry is a prospective, independent, consecutive collection of individual patient data.

RESULTS: A total of 628 patients (mean age 74.2 ± 9.7 years, 63.1% men) underwent TMVR between January 2011 and December 2012 in 25 centers in 8 European countries. The prevalent pathogenesis was functional mitral regurgitation (FMR) (n = 452 [72.0%]). The majority of patients (85.5%) were highly symptomatic (New York Heart Association functional class III or higher), with a high logistic EuroSCORE (European System for Cardiac Operative Risk Evaluation) (20.4 ± 16.7%). Acute procedural success was high (95.4%) and similar in FMR and degenerative mitral regurgitation (p = 0.662). One clip was implanted in 61.4% of patients. In-hospital mortality was low (2.9%), without significant differences between groups. The estimated 1-year mortality was 15.3%, which was similar for FMR and degenerative mitral regurgitation. The estimated 1-year rate of rehospitalization because of heart failure was 22.8%, significantly higher in the FMR group (25.8% vs. 12.0%, p[log-rank] = 0.009). Paired echocardiographic data from the 1-year follow-up, available for 368 consecutive patients in 15 centers, showed a persistent reduction in the degree of mitral regurgitation at 1 year (6.0% of patients with severe mitral regurgitation).

CONCLUSIONS: This independent, contemporary registry shows that TMVR is associated with high immediate success, low complication rates, and sustained 1-year reduction of the severity of mitral regurgitation and improvement of clinical symptoms.

Bibliographical data

Original languageEnglish
ISSN0735-1097
DOIs
Publication statusPublished - 02.09.2014

Comment Deanary

Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

PubMed 25169171